Alkem Laboratories Limited has announced the successful incorporation of its new wholly-owned subsidiary, Alkem Pharma Trading FZCO, based in Dubai, UAE. The entity, established on March 27, 2026, will serve as a strategic hub for exporting the company’s pharmaceutical products into African, South East Asian, and other non-UAE markets. The company holds a 100% stake in the new entity, which was capitalized with AED 3,670,000.
Strategic Expansion into International Markets
Alkem Laboratories continues to scale its global footprint with the formation of Alkem Pharma Trading FZCO. Registered in the Dubai Airport Free Zone, this new subsidiary is a critical component of the company’s international growth strategy. By establishing a dedicated trading arm in the UAE, the company aims to streamline its supply chain and enhance its distribution capabilities across African and South East Asian territories.
Financial Details of the Subsidiary
The establishment of the subsidiary involved a cash-based investment by Alkem Laboratories. The company subscribed to 3,670,000 equity shares, each valued at AED 10, bringing the total subscribed capital to AED 3,670,000. As a wholly-owned subsidiary, Alkem Laboratories maintains 100% control over the entity’s operations.
Future Outlook
The certificate of formation for the subsidiary was received on April 13, 2026. With this new operational base, Alkem is well-positioned to penetrate key emerging pharmaceutical markets outside of its existing primary domains. This move underscores the company’s commitment to diversifying its revenue streams through targeted global trade initiatives.
Source: BSE
